# Ipamorelin Dosage in the Research: Doses, Routes, and Half-Life > Ipamorelin dosage as it appears in the published research — the doses, routes, and ~2-hour human half-life studied in rats, swine, and human PK work. Research context only; no human dosing advice. What was given, to which species, by which route — the human pharmacokinetics, the rodent regimens, and why the popular combination protocols have no human dosing basis. ## Read this first This page records ipamorelin dosage the way the research records it — as doses given to animals or to volunteers in a study, never as a recommendation for any person. There is a real distinction here: a few studies measured how ipamorelin behaves in the body, but no study has established a safe or effective human dose for any everyday use. The numbers that *are* solid are pharmacokinetic. In humans, ipamorelin has a terminal half-life of about 2 hours, and its growth-hormone pulse peaks near 40 minutes after a dose [2]. The numbers people swap online — subcutaneous microgram protocols, often paired with CJC-1295 — have no peer-reviewed human dosing basis and are described below as exactly that: anecdotal, not a protocol. Nothing here tells anyone what to take. ## Doses used in the published studies Across the literature, ipamorelin has been administered very differently depending on the model: - **Human PK/PD study:** 4.21–140.45 nmol/kg IV over 15 minutes, as single doses [2]. - **Human Phase 2 ileus RCT:** 0.03 mg/kg IV twice daily for up to 7 days [3]. - **Rat bone-growth study:** 18, 90, and 450 µg/day subcutaneously, divided three times daily for 15 days [4]. - **Ferret cachexia study (2024):** 1–3 mg/kg intraperitoneally [5]. These are study doses tied to specific species and endpoints — not interchangeable, and not convertible into a human regimen. The rat bone study, for instance, divided its dose three times daily specifically to mimic pulsatile growth-hormone release [4], which is a study-design choice, not a dosing instruction. ## Half-life and routes studied The human pharmacokinetics are the most reliable dosing-adjacent numbers. Ipamorelin's terminal half-life in healthy human volunteers is about 2 hours (IV), with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg; the growth-hormone response is a single discrete pulse peaking near 40 minutes [2]. In rats, plasma clearance is roughly 5-fold lower than for GHRP-6. Routes studied span intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (rodent bone and body-composition studies — and the dominant route in community use), intranasal (rodent PK, ~20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Oral dosing applies only to engineered ipamorelin-derived analogs; ipamorelin itself is not orally bioavailable. The ipamorelin-derived oral analog NN703 illustrates the point — it was specifically modified for oral absorption and reached about 30% bioavailability in dogs [10]. ## How much cjc-1295 ipamorelin should i take The honest answer to *how much cjc-1295 ipamorelin should i take* is that no published source supports a human dose, and this site does not provide one. Community 'stack' protocols pair ipamorelin with CJC-1295 in subcutaneous microgram regimens, but those regimens have no peer-reviewed human dosing basis and rest on anecdote, not trials. The combination itself has never been tested in a controlled human study for any outcome [7]. What the literature offers is single-agent pharmacology — ipamorelin's ~2-hour half-life and 40-minute pulse [2] — not a combination dose. Anyone facing a real decision should consult a qualified professional and read the [Ipamorelin references](/references). ## How to reconstitute cjc-1295 ipamorelin 5mg On *how to reconstitute cjc-1295 ipamorelin 5mg*: the only general, non-prescriptive observation the research-supply literature supports is that ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling notes from the research-supply context, not a clinical preparation instruction and not a directive to prepare or inject anything. No validated human-use reconstitution protocol for a combination product exists, because no such product is approved. ## Stability and handling notes Ipamorelin's physical handling follows ordinary peptide behavior. It is supplied lyophilized and, in research settings, reconstituted with bacteriostatic water; the resulting solution is subject to degradation by heat and repeated freeze-thaw and is generally refrigerated. These observations come from the research-supply literature and describe how the material is stored and handled for laboratory purposes — they are not a clinical preparation protocol and carry no implication about human use. Because gray-market material is not subject to pharmaceutical quality assurance, the identity and purity of any given vial are unverified regardless of handling [3]. --- A star-chart reading of the ipamorelin record — the bright confirmed points (the 1998 selectivity, the ~2-hour human half-life) charted apart from the faint speculative ones, and the regulatory status read straight from the register; no clinic behind the atlas and nothing here dosed, compounded, prescribed, or sold.